Tiny bubbles, big ambition: Researchers have developed ultra-simple, biocompatible microrobots that can autonomously navigate the body, home in on tumors, and release cancer drugs on demand. Powered by enzymes and guided by the tumor’s own chemical signals, the so-called “bubble bots” mark a major step toward smart, clinically viable drug delivery systems.

Why does a high-fat diet raise liver cancer risk decades later? A new MIT study traces the answer to a slow cellular identity shift that turns survival into vulnerability.

Helping smokers quit remains one of the biggest opportunities to reduce tobacco-related disease. New recommendations urge healthcare professionals to include nicotine e-cigarettes among the evidence-based cessation options discussed with adult patients, while acknowledging that long-term safety data remain limited.

Indoor tanning beds do far more than darken the skin. A new study shows they nearly triple the risk of melanoma by causing widespread DNA damage across almost the entire skin surface — including areas rarely exposed to sunlight — offering the clearest molecular evidence yet of how tanning beds drive the deadliest form of skin cancer.

GSK has plans to takeover Nuvalent, a Boston-based clinical-stage biopharmaceutical company for 10.6 billion dollars. The biopharmaceutical firm is focused on creating precisely targeted oncology therapies.

From tuberculosis to lung cancer, a new personalised lung-on-chip model opens the door to studying respiratory diseases in a realistic human system for the first time.

Researchers have developed an AI-based platform that can map disease-related changes across the entire mouse body at cellular resolution. Using Mouse Mapper, the team identified widespread inflammation and previously unknown obesity-related damage to facial sensory nerves, and it found corresponding molecular signatures in human tissue.

A new study has identified that specialized immune cells within the glioblastoma tumor metabolize fructose to suppress immune responses and promote tumor growth. The study suggests that blocking this fructose metabolism may improve immunotherapy response.

Despite substantial investment in pharmaceutical R&D, clinical success rates remain low. As it stands, 90 % of drug candidates entering human trials fail due to unforeseen toxicity or limited efficacy in humans. A key contributor to this attrition is the limited predictive power of traditional preclinical models, particularly 2D cell cultures and animal studies, which often fall short in recapitulating the complexity of human biology. This gap is particularly evident in oncology and organ-specific toxicity assessments, where cellular context and microenvironmental interactions play a critical role in drug response.

The precise pH monitoring is crucial for the stability and performance of nanoparticles in drug delivery. Read how these biocompatible materials are developed and at what step the pH measurement is incorporated into the process.